Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
433
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents

Kelly S. ChienDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0001-6024-1613View further author information
ORCID Icon,
Caleb A. ClassDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0003-3130-3613View further author information
ORCID Icon,
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Yue WeiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Koji SasakiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Kiran NaqviDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Irene Ganan-GomezDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Hui YangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Kelly A. SoltysiakDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
,
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttp://orcid.org/0000-0001-7829-5249View further author information
ORCID Icon,
Kim-Anh DoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ORCID Iconhttp://orcid.org/0000-0001-8710-7131View further author information
ORCID Icon,
Hagop M. KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; View further author information
&
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
View further author information
 show all
Pages 1493-1499 | Received 25 Sep 2019, Accepted 18 Jan 2020, Published online: 08 Feb 2020

References

  • Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, et al. HLA-G: an immune checkpoint molecule. Adv Immunol. 2015;127:33–144.
  • Kang X, Kim J, Deng M, et al. Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors. Cell Cycle. 2016;15(1):25–40.
  • Suciu-Foca N, Feirt N, Zhang QY, et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol. 2007;178(11):7432–7441.
  • Kim-Schulze S, Scotto L, Vlad G, et al. Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells. J Immunol. 2006;176(5):2790–2798.
  • de Goeje PL, Bezemer K, Heuvers ME, et al. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer. Oncoimmunology. 2015;4(7):e1014242.
  • Dobrowolska H, Gill KZ, Serban G, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom. 2013;84(1):21–29.
  • Deng M, Gui X, Kim J, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605–609.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
  • Kim D, Pertea G, Trapnell C, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
  • Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
  • Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550.
  • Cella M, Dohring C, Samaridis J, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med. 1997;185(10):1743–1751.
  • Curran EK, Godfrey J, Kline J. Mechanisms of immune tolerance in leukemia and lymphoma. Trends Immunol. 2017;38(7):513–525.
  • Daver N, Basu S, Garcia-Manero G, et al. Phase IB/II study of nivolumab in combination with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML). Blood. 2016;128(22):763–763.
  • Zeidan AM, Knaus HA, Robinson TM, et al. A multi-center phase i trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure. Clin Cancer Res. 2018;24(15):3519–3527.
  • Stahl M, Goldberg AD. Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets. Curr Oncol Rep. 2019;21(4):37.
  • Liu Y, Bewersdorf JP, Stahl M, et al. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 2019;34:67–83.
  • John S, Chen H, Deng M, et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26(10):2487–2495.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.